iShares TIPS Bond ETF vs Viatris Inc — how do they compare? iShares TIPS Bond ETF trades at $104.65 (market cap $14.17B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while iShares TIPS Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares TIPS Bond ETF for 61 Days and Viatris Inc for 57 Days on average.
| TIP | VTRS | |
|---|---|---|
Market Cap | $14.17B | $20.03B |
Volume | 1,780,688 | 14,109,977 |
Sector | Fixed Income | Health |
52-Week High | $112.20 | $18.27 |
52-Week Low | $103.98 | $9.74 |
Typical Hold Time | 61 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
TIP trades at $104.24 with minimal daily movement (+0.06%). Technical indicators show a bearish bias with moving averages signaling caution while oscillators remain neutral. The ETF faces headwinds from rising bond yields and inflationary pressures affecting fixed income markets. Recent institutional activity shows Envestnet Asset Management increased its stake by 3.5% in the latest quarter.
The outlook remains challenging amid persistent bond market volatility and rising interest rates. Investment opportunity exists for inflation-protected exposure, though risks include continued yield increases and geopolitical tensions driving oil prices higher. Current technical weakness suggests cautious positioning may be warranted until market conditions stabilize.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Trailing returns across standard periods
Latest headlines on both assets
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →